Greenwich, CT – December 10, 2020 — Amulet Capital Partners, LP (“Amulet”), a middle-market private equity investment firm based in Greenwich, CT, focused exclusively on the healthcare sector, has closed the previously announced sale of its portfolio company, Synteract (the “Company”), a leading full-service CRO focused on the rapidly growing emerging biopharma segment across all phases of drug development, to Syneos Health (NASDAQ: SYNH), the only fully integrated biopharmaceutical solutions organization.
Ramsey Frank, Partner and Co-Founder of Amulet said, “This transaction represents the culmination of a very successful partnership for Amulet. From the outset of our investment, we recognized the growth opportunity in serving small and midsized biopharma clients. In partnership with management, we built a company tailored to the specific needs of this attractive customer segment, focusing around key therapeutic areas, adding resources to drive organic growth and operational excellence, and completing three accretive acquisitions. All of these initiatives resulted in a more than doubling of EBITDA under our ownership. We again express our sincere thanks and congratulations to the entire Synteract team.”
Amulet Partner Nick Amigone added, “The transaction validates Synteract’s differentiated value proposition in serving the emerging biopharma sector. We believe that Syneos Health will be an excellent steward for the Company as it grows and thrives within their organization. Amulet remains committed to the pharma outsourcing sector, both in growing our current portfolio companies and acquiring additional platforms.”
Jefferies LLC acted as sole financial advisor to Synteract on the transaction, and Skadden, Arps, Slate, Meagher and Flom LLP provided legal counsel.
Synteract®, a Syneos Health® company, is a leading full service CRO focused on the emerging biopharma segment. The Company’s multidisciplinary teams support biotech and pharmaceutical companies across all phases of drug development, providing deep expertise in oncology, dermatology, general medicine, infectious disease and vaccines, neuroscience, pediatrics, and rare and orphan diseases. Synteract has conducted nearly 4,000 studies on six continents in over 62 countries. To learn more about how Synteract is Bringing Clinical Trials to LifeTM by transforming insights to action and making therapies a reality, visit synteract.com and connect on LinkedIn and Twitter.
About Amulet Capital Partners, LP
Amulet Capital Partners, LP is a middle-market private equity investment firm based in Greenwich, CT, focused exclusively on the healthcare sector. Amulet seeks to achieve long-term capital appreciation through privately negotiated investments in companies. Amulet Capital Partners focuses on those segments it believes have the most attractive long-term fundamentals with a target investment size generally between $25 million to $150 million. For additional information, please visit www.amuletcapital.com.
Kent Place Communications